Risk Markers of Arterial Aging. The Paris Prospective Study III-2

NCT ID: NCT06079424

Last Updated: 2025-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

7500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-20

Study Completion Date

2033-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since May 2008, PPS3 is being following the CVD morbidity of 10157 healthy volunteers aged 50-75 years at baseline. In PPS3-2, we plan to re-invite survivors and volunteers of PPS3 to undergo a second physical examination. In particular, they will undergo a second high-precision carotid echotracking to measure vascular aging parameters and baroreflex sensitivity, permitting to study their respective dynamics. They will also underwent for the first time ultra fast echo of the radial artery to measure vascular aging parameters of the medium-sized arteries. According to fundings, blood samples will be taken and stored at -80°C in the whole population or in a subsample.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Stiffness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Level of vascular aging

community-based prospective longitudinal cohort

high-precision carotid echo-tracking

Intervention Type OTHER

evaluation of vascular aging parameters and baroreflex sensitivity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high-precision carotid echo-tracking

evaluation of vascular aging parameters and baroreflex sensitivity

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being enrolled in PPS3 and having signed an informed consent for PPS3-2

Exclusion Criteria

* Institutionalized participants
* Participants under guardianship
* Participants under judicial safeguard measure
Minimum Eligible Age

60 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Philippe Empana, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Institut National de la Santé Et de la Recherche Médicale, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre d'Investigation Précliniques

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-Philippe Empana, MD, PhD

Role: CONTACT

33153988020

Xavier Jouven, MD, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas Danchin

Role: primary

0153673535

Jean-Philippe Empana

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C21-67

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PREVENT: Promus BTK
NCT01500070 COMPLETED PHASE2
e-BioMatrix 6 Month DAPT France
NCT03461484 COMPLETED
LEADERS FREE II: BioFreedom™ Pivotal Study
NCT02843633 ACTIVE_NOT_RECRUITING NA
ROADSTER 3 Extended Follow-up Sub-Study
NCT06470815 ENROLLING_BY_INVITATION
Gangwon PCI Prospective Registry
NCT02038127 RECRUITING
Sapphire 3 CTO Study
NCT06358508 COMPLETED NA
VerifyNow French Registry
NCT00753753 COMPLETED